We are live on ! Find out more
XFOR icon

X4 Pharmaceuticals
XFOR

56 hedge funds and large institutions have $53.6M invested in X4 Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 9

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

8% more funds holding

Funds holding: 52 → 56 (+4)

0.01% more ownership

Funds ownership: 1.66% → 1.68% (+0.01%)

11% less capital invested

Capital invested by funds: $60.1M → $53.6M (-$6.54M)

68% less call options, than puts

Call options by funds: $49K | Put options by funds: $151K

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
56
Holders Change
+4
Holders Change %
+7.69%
% of All Funds
0.89%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
12
Increased
16
Reduced
9
Closed
8
Calls
$49K
Puts
$151K
Net Calls
-$102K
Net Calls Change
-$134K

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$4.44M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$747K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$509K
4
JP Morgan Chase
JP Morgan Chase
New York
+$495K
5
SM
Scoggin Management
New York
+$474K

Top Sellers

Rank Fund Capital Flow
1
CH
CVI Holdings
Delaware
-$2.37M
2
SCM
Sio Capital Management
New York
-$1.81M
3
BI
BVF Inc
California
-$1.34M
4
LCM
Lynwood Capital Management
Ontario, Canada
-$1.23M
5
Citadel Advisors
Citadel Advisors
Florida
-$906K
Name Holding Trade Value Shares
Change 		Change in
Stake
FDCDDQ
51
Federation des caisses Desjardins du Quebec
Quebec, Canada
$3.48K – – –
CA
52
Clearstead Advisors
Ohio
$1.83K – – –
TRCT
53
Tower Research Capital (TRC)
New York
$1K -$9.21K -314 -92%
Wells Fargo
54
Wells Fargo
California
$655 +$323 +11 +79%
Osaic Holdings
55
Osaic Holdings
Arizona
$460 -$4.34K -148 -89%
Commonwealth Equity Services
56
Commonwealth Equity Services
Massachusetts
$19 – – –
BNP Paribas Financial Markets
57
BNP Paribas Financial Markets
France
$6 – – –
Fidelity Investments
58
Fidelity Investments
Massachusetts
$3 – – –
CH
59
CVI Holdings
Delaware
– -$2.37M -79,397 Closed
SCM
60
Sio Capital Management
New York
– -$1.81M -60,865 Closed
BI
61
BVF Inc
California
– -$1.34M -44,922 Closed
PI
62
PEAK6 Investments
Illinois
– -$20.1K -673 Closed
CG
63
Cutler Group
California
– -$12K -407 Closed
HNWAG
64
High Net Worth Advisory Group
Florida
– -$1.09K -37 Closed
Bank of America
65
Bank of America
North Carolina
– -$270 -9 Closed
1 2
3

XFOR Hedge Fund Activity: Q1 2023 in Review

56 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q1 2023, worth a combined $53.6M — down 11% from $60.1M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new XFOR positions and 8 closed out — a net gain of 4 holders — while 16 added to existing stakes and 9 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $4.44M. The largest seller was CVI Holdings, exiting entirely with an estimated $2.37M sold.

  • 56 institutional investors held X4 Pharmaceuticals (XFOR) as of Q1 2023, up from 52 in Q4 2022.
  • Funds reported $53.6M of X4 Pharmaceuticals stock for Q1 2023, down 11% quarter-over-quarter.
  • 12 funds opened new X4 Pharmaceuticals positions in Q1 2023 and 8 closed out, a net change of +4 holders.
  • The largest X4 Pharmaceuticals buyer in Q1 2023 was Perceptive Advisors, an estimated $4.44M added.
  • The largest X4 Pharmaceuticals seller in Q1 2023 was CVI Holdings, an estimated $2.37M sold.

Based on aggregated 13F filings for Q1 2023.